vs
Side-by-side financial comparison of Abbott Laboratories (ABT) and ALCON INC (ALC). Click either name above to swap in a different company.
Abbott Laboratories is the larger business by last-quarter revenue ($11.5B vs $2.6B, roughly 4.4× ALCON INC). Abbott Laboratories runs the higher net margin — 15.5% vs 6.8%, a 8.7% gap on every dollar of revenue. On growth, Abbott Laboratories posted the faster year-over-year revenue change (4.4% vs 4.0%).
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.
ABT vs ALC — Head-to-Head
Income Statement — Q4 2025 vs Q2 2025
| Metric | | |
|---|---|---|
| Revenue | $11.5B | $2.6B |
| Net Profit | $1.8B | $176.0M |
| Gross Margin | 57.0% | 53.5% |
| Operating Margin | 19.6% | 9.5% |
| Net Margin | 15.5% | 6.8% |
| Revenue YoY | 4.4% | 4.0% |
| Net Profit YoY | -80.8% | -21.1% |
| EPS (diluted) | $1.01 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.5B | — | ||
| Q3 25 | $11.4B | — | ||
| Q2 25 | $11.1B | $2.6B | ||
| Q1 25 | $10.4B | — | ||
| Q4 24 | $11.0B | — | ||
| Q3 24 | $10.6B | — | ||
| Q2 24 | $10.4B | $2.5B | ||
| Q1 24 | $10.0B | — |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.8B | $176.0M | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $9.2B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.3B | $223.0M | ||
| Q1 24 | $1.2B | — |
| Q4 25 | 57.0% | — | ||
| Q3 25 | 55.4% | — | ||
| Q2 25 | 56.4% | 53.5% | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 55.6% | 55.0% | ||
| Q1 24 | 55.2% | — |
| Q4 25 | 19.6% | — | ||
| Q3 25 | 18.1% | — | ||
| Q2 25 | 18.4% | 9.5% | ||
| Q1 25 | 16.3% | — | ||
| Q4 24 | 17.4% | — | ||
| Q3 24 | 17.5% | — | ||
| Q2 24 | 16.1% | 12.7% | ||
| Q1 24 | 13.9% | — |
| Q4 25 | 15.5% | — | ||
| Q3 25 | 14.5% | — | ||
| Q2 25 | 16.0% | 6.8% | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 84.1% | — | ||
| Q3 24 | 15.5% | — | ||
| Q2 24 | 12.5% | 8.9% | ||
| Q1 24 | 12.3% | — |
| Q4 25 | $1.01 | — | ||
| Q3 25 | $0.94 | — | ||
| Q2 25 | $1.01 | $0.35 | ||
| Q1 25 | $0.76 | — | ||
| Q4 24 | $5.26 | — | ||
| Q3 24 | $0.94 | — | ||
| Q2 24 | $0.74 | $0.45 | ||
| Q1 24 | $0.70 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.9B | $1.4B |
| Total DebtLower is stronger | $12.9B | — |
| Stockholders' EquityBook value | $52.1B | $22.1B |
| Total Assets | $86.7B | $31.4B |
| Debt / EquityLower = less leverage | 0.25× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.9B | — | ||
| Q3 25 | $7.7B | — | ||
| Q2 25 | $7.3B | $1.4B | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | $8.0B | — | ||
| Q3 24 | $7.8B | — | ||
| Q2 24 | $7.2B | $1.4B | ||
| Q1 24 | $6.7B | — |
| Q4 25 | $12.9B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $14.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $52.1B | — | ||
| Q3 25 | $51.0B | — | ||
| Q2 25 | $50.6B | $22.1B | ||
| Q1 25 | $48.8B | — | ||
| Q4 24 | $47.7B | — | ||
| Q3 24 | $39.8B | — | ||
| Q2 24 | $39.3B | $20.9B | ||
| Q1 24 | $38.8B | — |
| Q4 25 | $86.7B | — | ||
| Q3 25 | $84.2B | — | ||
| Q2 25 | $84.0B | $31.4B | ||
| Q1 25 | $81.4B | — | ||
| Q4 24 | $81.4B | — | ||
| Q3 24 | $74.4B | — | ||
| Q2 24 | $73.0B | $29.7B | ||
| Q1 24 | $72.5B | — |
| Q4 25 | 0.25× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.30× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | — |
| Free Cash FlowOCF − Capex | $2.6B | — |
| FCF MarginFCF / Revenue | 22.9% | — |
| Capex IntensityCapex / Revenue | 6.0% | — |
| Cash ConversionOCF / Net Profit | 1.87× | — |
| TTM Free Cash FlowTrailing 4 quarters | $7.4B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3B | — | ||
| Q3 25 | $2.8B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $2.9B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $933.0M | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $627.0M | — |
| Q4 25 | 22.9% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 20.2% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 6.3% | — |
| Q4 25 | 6.0% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 4.5% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 4.0% | — |
| Q4 25 | 1.87× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 0.84× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
